Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 293.00 | |
5 mg | In stock | $ 722.00 | |
10 mg | In stock | $ 987.00 | |
25 mg | In stock | $ 1,520.00 | |
50 mg | In stock | $ 1,980.00 | |
100 mg | In stock | $ 2,500.00 |
Description | AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer. |
Synonyms | NRC-AN-019, NRC-019 |
Molecular Weight | 517.43 |
Formula | C25H17F6N5O |
CAS No. | 879507-25-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AN-019 879507-25-2 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl NRC019 NRC-AN019 AN 019 NRC 019 NRC-AN-019 AN019 NRC-019 NRC-AN 019 NRC inhibitor inhibit